General information about company	
Scrip code*	543998
NSE Symbol*	VALIANTLAB
MSEI Symbol*	NOTLISTED
ISIN*	INE0JWS01017
Name of company	Valiant Laboratories Limited
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-04-2026
Date of end of financial year	31-03-2027
Date of board meeting when results were approved	02-11-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	27-10-2026
Description of presentation currency	INR
Level of rounding	Lakhs
Reporting Type	Quarterly
Reporting Quarter	Second quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited
Segment Reporting	Single segment
Description of single segment	Manufactoring Chemical
Start date and time of board meeting	02-11-2026 16:00
End date and time of board meeting	02-11-2026 17:20
Whether cash flow statement is applicable on company	Yes

Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest	NA

mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.		
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?		No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?		
(b) If answer to above question is No, please explain the reason for not complying.		
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?		Yes
Latest Date on which RPT policy is updated		11-02-2026
Indicate Company website link for updated RPT policy of the Company		https://www.valiantlabs.in/assets/images/investors/policy_on_dealing_with_related_party_transactions.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?		No
No. of times funds raised during the quarter		
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No	This disclosure is not applicable, as the Company has not defaulted on any of its loans or debt securities.

Valiant Laboratories

Format for Disclosure of Related Party Transactions (

Sr. No.	Details of	Details of the		Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are		Additional disclosure of related party transactions - applicable only in case the related pa							
													In case any financial indebtedness is				Details of the loans, inter-corporate dep			
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured
1	Valiant Laboratories Limited	Santosh Vora	Executive Director(MD)	Remuneration		27.00	NA			13.50	0.00	0.00								
2	Valiant Laboratories Limited	Paresh Shah	Executive Director(CFO)	Remuneration		20.00	NA			10.00	0.00	0.00								
3	Valiant Laboratories Limited	Valiant Advanced Sciences Private Limited	Wholly Owned Subsidiary	Investment		16505.80	NA			0.00	16505.80	16505.80								
4	Valiant Laboratories Limited	Valiant Advanced Sciences Private Limited	Wholly Owned Subsidiary	Sale of goods or services		10000.00	NA			1195.04	660.25	0.79								
5	Valiant Laboratories Limited	Valiant Advanced Sciences Private Limited	Wholly Owned Subsidiary	Any other transaction	Other Reimbursement	500.00	NA			19.18	13.20	6.56								
6	Valiant Laboratories Limited	Valiant Advanced Sciences Private Limited	Wholly Owned Subsidiary	Any other transaction	Reimbursement of Asset	20.00	NA			11.34	0.00	11.34								

7	Valiant Laboratories Limited	Valiant Advanced Sciences Private Limited	Wholly Owned Subsidiary	Any other transaction	Trade Advance Given	10000.00	NA			1974.61	2930.74	4905.35							
8	Valiant Laboratories Limited	Valiant Advanced Sciences Private Limited	Wholly Owned Subsidiary	Purchase of goods or services		10000.00	NA			2517.62	0.00	76.83							
9	Valiant Laboratories Limited	Valiant Organics Limited	Ultimate Holding Company	Purchase of goods or services		30000.00	NA			6860.34	5496.06	4096.13							
10	Valiant Laboratories Limited	Valiant Organics Limited	Ultimate Holding Company	Any other transaction	Reimbursement of Asset	40.00	NA			34.02	0.00	34.02							
11	Valiant Laboratories Limited	Valiant Organics Limited	Ultimate Holding Company	Any other transaction	Other Reimbursement	500.00	NA			12.22	0.00	2.50							
12	Valiant Laboratories Limited	Shantilal Vora	Non Executive Director	Any other transaction	Sitting Fees		NA			0.38	0.00	0.00							
13	Valiant Laboratories Limited	Aarti Pharmalabs Limited	Other Related Party	Any other transaction	Security Deposit received against Leave & License Agreement executed	96.14	NA			0.00	96.14	96.14							
14	Valiant Laboratories Limited	Aarti Pharmalabs Limited	Other Related Party	Purchase of goods or services		1000.00	NA			180.68	31.11	35.49							

15	Valiant Laboratories Limited	Aarti Pharmalabs Limited	Other Related Party	Sale of goods or services		1000.00	NA			0.00	290.33	0.00							
16	Valiant Laboratories Limited	Aarti Pharmalabs Limited	Other Related Party	Any other transaction	Rent received	500.00	NA			177.00	0.00	29.50							
17	Valiant Laboratories Limited	Aarti Pharmalabs Limited	Other Related Party	Any other transaction	Other Reimbursement	1500.00	NA			538.69	65.81	230.92							
18	Valiant Advanced Sciences Private Limited	Valiant Organics Limited	Ultimate Holding Company	Sale of goods or services		5000.00	NA			166.90	28.22	50.62							
19	Valiant Advanced Sciences Private Limited	Aarti Pharmalabs Limited	Other Related Party	Sale of goods or services		10000.00	NA			2179.34	49.69	1135.12							
20	Valiant Advanced Sciences Private Limited	Aarti Pharmalabs Limited	Other Related Party	Purchase of goods or services		1000.00	NA			549.12	0.00	548.70							
21	Valiant Advanced Sciences Private Limited	Alchemie Speciality Chemicals Pvt.Ltd	Ultimate Holding Company	Sale of goods or services		2500.00	NA			512.17	127.53	217.25							
22	Valiant Advanced Sciences Private Limited	Alchemie Finechem Private Limited	Other Related Party	Sale of goods or services			NA	18.51	02-11-2026	18.51	0.00	18.51							

23	Valiant Advanced Sciences Private Limited	Jyotibhushan Singh	Executive Director	Remuneration		25.00	NA			10.00	0.00	0.00							
24	Valiant Advanced Sciences Private Limited	Ganesh Polychem Limited	Other Related Party	Sale of goods or services			NA	10.33	02-11-2026	10.33	0.00	10.33							
Total value of transaction during the reporting period										16990.99									

ty transaction relates	
osits, advances or	
Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	Notes